Trials / Unknown
UnknownNCT01725906
Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication
Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
We aimed to compare the efficacy of genotypic resistance guided sequential therapy vs. empiric therapy in the third line therapy. Factors affecting the eradication rates, including the antibiotic resistance, CYP2C19 polymorphism, CagA and VacA status will also be assessed.
Detailed description
The primary aim of this study is to compare the regimens selected using either one of the method (1) genotypic resistance guided versus (2) medication history guided therapy. (rather than to compare the efficacy of any drugs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | empirical therapy | 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus 2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus 3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs 4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14 |
| DRUG | Genotypic resistance guided therapy | 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus 2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus 3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs 4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14 |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2017-05-01
- Completion
- 2017-12-01
- First posted
- 2012-11-14
- Last updated
- 2017-05-08
Locations
2 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01725906. Inclusion in this directory is not an endorsement.